Preoperative chemotherapy in the colorectal cancer patients with synchronous metastases to the liver. A vote for YES by Wełnicka-Jaśkiewicz, Marzena
282
Short review
NOWOTWORY Journal of Oncology 
2018, volume 68, number 5–6, 282–285
DOI: 10.5603/NJO.2018.0045
© Polskie Towarzystwo Onkologiczne
ISSN 0029–540X
www.nowotwory.edu.pl
Department of Oncology and Radiotherapy, Chemotherapy Day Unit, Medical University of Gdańsk, Poland
Preoperative chemotherapy in the colorectal cancer patients with 
synchronous metastases to the liver 
A vote for YES
Marzena Wełnicka-Jaśkiewicz
The increasing effectiveness of chemotherapy (cht) has led to a rise in interest in preoperative neoadjuvant treatment 
preceding resection of colorectal metastases. Preoperative chemotherapy is often undertaken as a method of natural 
evaluation of the progress of metastases before starting metastasectomy, in particular in patients with synchronous 
liver metastases. This method also has the potential of reducing potentially unresectable metastases and allowing for 
their safe resection. Optimal selection of patients, the choice of treatment regimen, and timing as well as the most 
beneficial method of integrating chemotherapy with the surgery has not been defined.
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Introduction
With regards to the frequency of incidence, colorectal 
cancer ranks third, whilst the liver remains the most frequ-
ent location of metastases, affecting about 50% patients 
[1]. Currently the only potential possibility of cure is the 
resection of metastases, undertaken first of all in patients 
with isolated lesions in the liver. However, even after their 
complete resection and combining modern systemic treat-
ment regimes, only in 20% of cases is the treatment radical, 
whereas in other cases the disease progresses. At the mo-
ment of diagnosing colorectal cancer, 20–25% have stage IV 
of the disease, including 15–20% patients with synchronous 
metastases, most frequently located in the liver [2].
Available literature presents at least a few definitions 
of synchronous metastases: most often they are defined as 
metastases which were diagnosed at the same time as the 
primary focus or in a short post-operative period. Irrespec-
tive of the treatment, the presence of synchronous liver 
metastases is an adverse prognostic factor resulting from 
an adverse cancer biology, and, in comparison with meta-
chronous metastases, can be characterised with a shorter 
survival period and a larger rate of recurrence. These lesions 
are most frequently located in the liver which, among others, 
may result from the fact that some micro-metastases have 
not been diagnosed earlier [3]. The rate of five and ten-year 
survivals after potentially radical metastases resection varies 
from 37% to 58% and from 20% to 25% respectively [4]. 
A much worse prognoses in patients with synchronous me-
tastases in the liver can be caused by the delayed diagnosis 
of a primary tumour or more aggressive tumour biology.
Although the correct treatment of colorectal cancer 
patients with synchronous liver metastases poses a signi-
ficant problem, there are no definite treatment guidelines. 
The majority of publications concerning this issue contain 
observational studies carried out on a relatively small gro-
up of patients or present systematic literature overviews. 
Significant heterogenicity and the small size of the studied 
group makes it difficult to create a clinical study which would 
provide an answer to the question about which of the che-
motherapy forms (pre- or postoperative) is more efficient.
Preoperative (neoadjuvant) chemotherapy of 
synchronous liver metastases 
The basic treatment standard for patients with syn-
chronous liver metastases is surgical intervention, yet, at 
the moment of diagnosing, the majority of patients do not 
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qualify for surgery on account of the advanced stage of the 
metastases. Recent improvements in treatment results is 
both the outcome of better surgical techniques and more 
effective chemotherapy [5]. Current guidelines concerning 
metastases resection allow for the removal of all lesions with 
an appropriate margin (R0) and for conserving a functional 
part of the liver with a volume of at least 30%; at the same 
time, preoperative systemic treatment has been increasingly 
used [6]. The arguments for such strategy comprise first of 
all the elimination of all possible micro-metastases and 
a potential chance of cytoreduction making R0 resection 
possible. At the same time, preoperative chemotherapy 
allows for identifying those patients who do not respond 
to systemic treatment or in whose case progression occurs; 
subsequently intrusive and unnecessary surgery can be 
avoided. Moreover, during pre-operative chemotherapy 
lasting a few months, usually some cht, some so-called silent 
foci are revealed, which leads to a change in the treatment 
plan. The majority of authors also emphasise the possibility 
of evaluating the response to chemotherapy, which may 
have prognostic significance and be helpful in planning 
further treatment [7].
Combining surgery with chemotherapy has become 
a generally accepted therapeutic option, whilst the actual 
sequence of treatment is still widely debated. Randomised 
clinical trials carried out by the EORTC (European Organi-
zation for Research and Treatment of Cancer) have showed 
that peri-operative chemotherapy significantly prolongs 
disease-free survival and insignificantly increases overall 
survival [8].
During the preparation for the “Debates”, my opponent 
and I adopted an assumption that the primary colorectal 
tumour had been removed in the first stage of the treat-
ment in order to avoid cancer-related symptoms as the 
most probable source of the next metastases. The classi-
cal course of treatment in the majority of cases comprises 
neoadjuvant chemotherapy (3–6 months), which should be 
strictly controlled by imaging diagnostics. The objective of 
such a procedure is to decrease the metastases and increase 
the chance for R0 surgery. Such a course of action allows 
for the identification of those foci which do not respond 
to chemotherapy. The authors of the relatively “old” study 
from the Memorial Sloan-Kettering Cancer Center analysed 
the documentation of 330 patients with synchronous liver 
metastases [9]. Out of 106 patients with similar clinical char-
acteristics, in whom the primary tumour was resected first, 
one half of the patients received neoadjuvant chemother-
apy, whilst the rest underwent the resection of metastases 
within the period of 4 to 14 weeks of the removal of the pri-
mary focus; most of them received adjuvant chemotherapy 
afterwards. The rate of 5-year overall survival in the group 
receiving neoadjuvant treatment and adjuvant treatment 
was not statistically significant, totalling 43% and 35% re-
spectively (p = 0.35). A significant observation resulting from 
the discussed study was that the response to neoadjuvant 
surgery was a factor affecting the improvement of survival. 
The subgroup of patients in whom no progression occurred 
after neoadjuvant chemotherapy benefited significantly 
from the treatment with respect to OS in comparison with 
patients on adjuvant treatment (85% vs 35%, p = 0.03). The 
authors emphasised that in the high risk group, with a possi-
ble presence of occult metastases, the haste in deciding on 
a fast surgical intervention is not indicated because during 
the neoadjuvant chemotherapy some new metastases a fast 
progression of the ones already existing may be diagnosed 
or, thus allowing to avoid unnecessary surgery.
A retrospective Korean study evaluated the treatment 
results of patients with synchronous liver metastases, 53 
patients received preoperative chemotherapy, whereas 96 
were operated on first and then underwent chemothera-
py [10]. The rate of the 3-year disease-free survival (DFS) 
in the group with preoperative chemotherapy and with 
surgery first was 31.7 and 20.4% respectively (p = 0.015%), 
whilst there was no significant difference with regards to 
overall survival. In the second stage of the analysis, 32 pairs 
of patients with similar characteristics were selected from 
both groups; the DFS rate was significantly higher in the 
patients receiving preoperative chemotherapy (34.2% vs 
16.8%, p = 0.019), whilst, likewise, no significant differences 
were found with regards to OS (74% vs 62.2%, p = 0.244). The 
authors of the study emphasise that in the case of multiple 
liver metastases, the identification of the patients respond-
ing to chemotherapy is as important as obtaining complete 
remission (CR). They believe that in such cases pre-operative 
chemotherapy is necessary, especially in cases where it is 
doubtful whether R0 resection is possible.
Another proposed treatment option for synchronous 
metastases was a three-stage procedure proposed by Men-
tha et al., addressed first of all to patients without any risk of 
potential significant conditions resulting from the primary 
focus and defined as “reversed” liver first resection [11]. 
The first stage of the treatment was chemotherapy (2–6 
courses), then the resection of metastases from the liver 
and — after a few weeks — the resection of the primary 
focus. The response to systemic treatment was obtained in 
80% patients and in more than a half the symptoms related 
to the primary tumour receded during chemotherapy. The 
rate of R0 resectability was 80%, whilst the OS rate in the 
first, second, third and fourth year was 85%, 79%, 71% and 
56% respectively. Unfortunately, with regards to the small 
number of patients participating in this study, its value is 
quite limited.
In recent years, an increasing number of reports con-
cerning the simultaneous resection of primary focus and 
liver metastases have been published; the objective of such 
treatment was to minimise the risk of progression and to 
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avoid two surgeries [12]. It must be taken into consideration, 
however, that an appropriate patient qualification is nec-
essary for such procedures, and only well selected patients 
should be candidates for such treatment. It is possible to use 
both preoperative and post-operative chemotherapy, yet 
there are no direct studies comparing these two strategies.
A lot of information may be gained from a retrospective 
analysis carried out on the basis of a prospectively gathered 
database concerning the treatment strategies of patients 
with synchronous liver metastases [13]. The decisions con-
cerning treatment have always been taken in multi-disci-
plinary team (MDT) discussions. The most significant char-
acteristics determining the choice of the treatment were the 
location and the stage of the primary focus and metastases, 
and in the case of neoadjuvant chemotherapy — also the 
treatment response. Surgical options taken into consider-
ation comprised the classical strategy (primary focus first 
and then the metastases), synchronous resection or the liver 
first option. More than 90% of patients received chemother-
apy, out of which 73% — preoperative. The survival period 
of patients who received chemotherapy at any treatment 
stage, was 10 months longer than in the case of those who 
were not systemically treated. The median survival period 
for the classical and synchronic strategy was 40.3 and 12.5 
months (p = 0.021); whilst for the reverse strategy no me-
dian was obtained. It must be stressed that the classical 
procedure was most frequently used, and only in a few 
patients was the decision taken to resect metastases at the 
first stage of surgical intervention. The authors of the study 
stressed that irrespectively of the selected surgical option, 
the treatment results seem to be promising and the results 
of the analysis that has been carried out point out that the 
presence of more than five metastases, an age of 60 years or 
above, and R2 resection, are all adverse prognostic factors.
It must be remembered that irrespective of the choice 
of the treatment regimen, the duration of neoadjuvant che-
motherapy should be limited and a radiological evaluation 
of the response should be performed every 6 weeks and 
surgery carried out as soon as the metastases turn out to 
be resectable. Some reports concerning the liver toxicity of 
preoperative chemotherapy (oxaliplatin, irinotecan) mani-
festing mostly as steatosis, nodular regenerative hypertro-
phy or cirrhosis, raise some concern [14].
These reports concern however not only preoperative treat-
ment, but also adjuvant. Currently, it is believed that the best 
candidates for preoperative chemotherapy are patients with 
poorer prognostic factors and with threshold metastases [15]. 
Summary 
Colorectal cancer patients with synchronous liver me-
tastases make up a relatively narrow and heterogenous 
group that randomised clinical trials which could provide an 
answer to the question whether pre-operative or post-op-
erative chemotherapy is more efficient, may not only be 
impossible but also unethical. The choice of the appro-
priate treatment option is determined by many variables 
which could significantly affect treatment decisions. That 
is why, the solution to this problem lies, in my opinion, in 
the creation of multidisciplinary teams taking individual 
therapeutic decisions, as already happens in other countries. 
To generalise, without taking into consideration an in-
dividual approach to the patient, it can be observed that 
more benefits lie in neoadjuvant than adjuvant therapy, as 
the preoperative chemotherapy allows for:
1. the elimination of micro-metastases and the reduction of 
cancer foci, thus increasing the chances of R0 resection;
2. the possibilities of evaluating the treatment response, 
which might have prognostic significance and be helpful 
in treatment planning;
3. the identification of patients who do not respond to che-
motherapy or those where progression occurs, which 
allows for the avoidance of surgery;
4. the delay of metastases resection by 3–6 months (for the 
period of the duration of chemotherapy), which makes 
it possible to reveal clinically silent foci.
At the same time, the concern that preoperative chemo-
therapy might result in the fact that resectable lesions may 
become nonresectable is not justified. It must be stressed 
that preliminary chemotherapy improves the selection of 
patients for the resection of liver metastases.
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